Revelation Biosciences (REVB) director Carver’s tax-related sale of 1,661 shares disclosed

Rhea-AI Filing Summary

Revelation Biosciences director Jennifer Carver reported a routine share sale tied to tax withholding. On February 3, 2026, 1,661 shares of common stock were sold at a weighted average price of $1.87 per share, solely to cover tax obligations from vesting restricted stock awards.

After this mandatory transaction, Carver beneficially owned 12,758 shares of Revelation Biosciences common stock on a direct basis. All share amounts reflect a 1-for-4 reverse stock split effective January 28, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CARVER JENNIFER

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,661	$1.87	$3K

Holdings After Transaction: Common Stock — 12,758 shares (Direct)

Footnotes (1)

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARVER JENNIFER

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		F		1,661(1)(2)	D	$1.87(3)	12,758(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

2. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ J.P. Galda, as attorney-in-fact for Jennifer Carver	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REVB director Jennifer Carver report?

Jennifer Carver reported a sale of 1,661 shares of Revelation Biosciences common stock. The shares were sold on February 3, 2026 at a weighted average price of $1.87 per share, in connection with tax withholding on vested restricted stock awards.

Why were Jennifer Carver’s REVB shares sold in this Form 4 filing?

The shares were sold by the issuer on Jennifer Carver’s behalf solely to satisfy required tax obligations from the vesting of restricted stock awards. The filing states the transaction was mandatory and she did not exercise investment discretion regarding the sale.

How many REVB shares does Jennifer Carver own after this transaction?

After the reported transaction, Jennifer Carver beneficially owned 12,758 shares of Revelation Biosciences common stock. The filing indicates these shares are held directly in her name, following the sale of 1,661 shares for tax withholding purposes.

What price did the REVB shares sell for in Jennifer Carver’s Form 4?

The filing reports a weighted average sale price of $1.87 per share. It notes the 1,661 shares were sold in multiple trades at prices ranging from $1.87 to $1.88, and details by price level are available upon request from the company or regulators.

How did a reverse stock split affect Jennifer Carver’s REVB share counts?

All share amounts in the filing reflect a 1-for-4 reverse stock split effective January 28, 2026. This means the reported 1,661 shares sold and 12,758 shares owned after the transaction already incorporate the adjusted share numbers post-split.

What does transaction code F mean in the REVB Form 4 for Jennifer Carver?

Transaction code F indicates a sale of shares to cover tax withholding obligations related to the vesting of equity awards. In this case, the issuer sold 1,661 shares on Jennifer Carver’s behalf to satisfy taxes from vested restricted stock awards.